Top 5 Target	Count

BTX(Botulinum toxin)	2
CDK4(Cyclin-dependent kinase 4)	2
PTH1R(Parathyroid hormone receptor)	1
c-Met(Hepatocyte growth factor receptor)	1
CDK12(cyclin dependent kinase 12)	1

Drugs associated with XOMA Royalty Corp.

Resigratinib

Target

FGFR2 x FGFR3

Mechanism

FGFR2 antagonists [+1]

Active Org.

Kinnate Biopharma, Inc. [+1]

Originator Org.

Kinnate Biopharma, Inc.

Active Indication

Solid tumor [+2]

Inactive Indication

Advanced cancer [+2]

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date-

XOMA-3AB

Target

BTX

Mechanism

BTX inhibitors

Active Org.

Nanotherapeutics, Inc. [+2]

Originator Org.

University of California

Active Indication

Poisoning

Inactive Indication

Botulism

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date-

Xoma-3E

Target

BTX

Mechanism

BTX inhibitors

Active Org.

Resilience Government Services, Inc. [+1]

Originator Org.

XOMA Royalty Corp.

Active Indication

Botulism

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with XOMA Royalty Corp.

NCT05242822

/ Active, not recruitingPhase 1

A Phase 1/1b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-3248, an oral small molecule FGFR inhibitor, in adults with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations.

Start Date18 Apr 2022

Sponsor / Collaborator

Kinnate Biopharma, Inc.

NCT03473236

/ CompletedPhase 1

A Phase 1A Single Ascending Dose and Multiple Ascending Dose Double-Blind, Placebo-Controlled, Randomized Trial of Oral Inhalation PK10571 in Healthy Adult Subjects

This is a phase 1A randomized double blind placebo controlled single ascending dose and multiple ascending dose trial of inhaled PK10571 (GB002) in healthy adult subjects.

Start Date06 Sep 2017

Sponsor / Collaborator

GB002, Inc.

[+2]

EUCTR2016-001275-80-DE

/ Not yet recruitingPhase 2

An Open-Label Study of XOMA 358, with Optional Dose Escalation, in Patients with Congenital Hyperinsulinism -

Start Date25 Aug 2016

Sponsor / Collaborator

XOMA (US) LLC

100 Clinical Results associated with XOMA Royalty Corp.

0 Patents (Medical) associated with XOMA Royalty Corp.

146

Literatures (Medical) associated with XOMA Royalty Corp.

19 Jul 2024·ORGANIC PROCESS RESEARCH & DEVELOPMENT

Efficient, Scalable Synthesis of Functionalized Pyrrolo[2,1-f][1,2,4]triazines

Author: Chen, Ce ; Feng, Lei ; Li, Zhongzhen ; Pack, Shawn K.

An efficient, scalable synthesis of functionalized 5-fluoropyrrolo[2,1-f][1,2,4]triazines was developed from readily available starting materials.The synthesis is highlighted by a safe, Cu mediated difluoroacetate addition to vinyl TMS, selective formylation of 3-fluoropyrrole and sequential imine formation followed by cyclization to the triazine core.Addition of other electrophiles to 3-fluoropyrrole was also shown to be equally selective.

01 Dec 2022·Bioorganic & medicinal chemistry

The discovery of (1R, 3R)-1-(3-chloro-5-fluorophenyl)-3-(hydroxymethyl)-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile, a potent and selective agonist of human transient receptor potential cation channel subfamily m member 5 (TRPM5) and evaluation of as a potential gastrointestinal prokinetic agent

Article

Author: Myers, R ; Raveglia, L F ; Aldegheri, L ; Virginio, C ; Ton-Nu, T ; Bianchi, F ; Feriani, A ; Tassini, S ; Wang, H ; Miura, J ; Piccoli, L ; Brault, L ; Barilli, A ; Sabat, M ; Tyhonas, J ; Lingard, I ; Brodbeck, D

This publication details the discovery of a series of selective transient receptor potential cation channel subfamily M member 5 (TRPM5) agonists culminating with the identification of the lead compound (1R, 3R)-1-(3-chloro-5-fluorophenyl)-3-(hydroxymethyl)-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile (39). We describe herein our biological rationale for agonism of the target, the examination of the then current literature tool molecules, and finally the process of our discovery starting with a high throughput screening hit through lead development. We also detail the selectivity of the lead compound 39 versus related family members TRPA1, TRPV1, TRPV4, TRPM4 and TRPM8, the drug metabolism and pharmacokinetics (DMPK) profile and in vivo efficacy in a mouse model of gastrointestinal motility.

01 Dec 2019·Journal for immunotherapy of cancerQ2 · MEDICINE

α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

Q2 · MEDICINE

ArticleOA

Author: To, M D ; Buchmann, T ; Paniagua, R ; Quezada, S A ; Liang, B ; Adoumie, M ; Krummel, M F ; Balmain, A ; Meyer, D S ; Binnewies, M ; Mori, H ; Malato, J ; Mirza, A ; Akhurst, R J ; Hann, B C ; Broz, M L ; Dodagatta-Marri, E ; Rosenblum, M D ; Sheppard, D ; Arce Vargus, F ; Wu, D ; Li, O ; Reeves, M Q ; Del Rosario, R

BACKGROUND:

Checkpoint blockade immunotherapy has improved metastatic cancer patient survival, but response rates remain low. There is an unmet need to identify mechanisms and tools to circumvent resistance. In human patients, responses to checkpoint blockade therapy correlate with tumor mutation load, and intrinsic resistance associates with pre-treatment signatures of epithelial mesenchymal transition (EMT), immunosuppression, macrophage chemotaxis and TGFβ signaling.

METHODS:

To facilitate studies on mechanisms of squamous cell carcinoma (SCC) evasion of checkpoint blockade immunotherapy, we sought to develop a novel panel of murine syngeneic SCC lines reflecting the heterogeneity of human cancer and its responses to immunotherapy. We characterized six Kras-driven cutaneous SCC lines with a range of mutation loads. Following implantation into syngeneic FVB mice, we examined multiple tumor responses to α-PD-1, α-TGFβ or combinatorial therapy, including tumor growth rate and regression, tumor immune cell composition, acquired tumor immunity, and the role of cytotoxic T cells and Tregs in immunotherapy responses.

RESULTS:

We show that α-PD-1 therapy is ineffective in establishing complete regression (CR) of tumors in all six SCC lines, but causes partial tumor growth inhibition of two lines with the highest mutations loads, CCK168 and CCK169. α-TGFβ monotherapy results in 20% CR and 10% CR of established CCK168 and CCK169 tumors respectively, together with acquisition of long-term anti-tumor immunity. α-PD-1 synergizes with α-TGFβ, increasing CR rates to 60% (CCK168) and 20% (CCK169). α-PD-1 therapy enhances CD4 + Treg/CD4 + Th ratios and increases tumor cell pSmad3 expression in CCK168 SCCs, whereas α-TGFβ antibody administration attenuates these effects. We show that α-TGFβ acts in part through suppressing immunosuppressive Tregs induced by α-PD-1, that limit the anti-tumor activity of α-PD-1 monotherapy. Additionally, in vitro and in vivo, α-TGFβ acts directly on the tumor cell to attenuate EMT, to activate a program of gene expression that stimulates immuno-surveillance, including up regulation of genes encoding the tumor cell antigen presentation machinery.

CONCLUSIONS:

We show that α-PD-1 not only initiates a tumor rejection program, but can induce a competing TGFβ-driven immuno-suppressive program. We identify new opportunities for α-PD-1/α-TGFβ combinatorial treatment of SCCs especially those with a high mutation load, high CD4+ T cell content and pSmad3 signaling. Our data form the basis for clinical trial of α-TGFβ/α-PD-1 combination therapy (NCT02947165).

189

News (Medical) associated with XOMA Royalty Corp.

19 Dec 2024

·www.globenewswire.com

XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about January 15, 2025, to respective holders of record at the close of business on January 3, 2025. About XOMA Royalty CorporationXOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about XOMA Royalty and its portfolio, please visit www.xoma.com or follow the Company on LinkedIn. As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available. Investor contact:Media contact:Juliane SnowdenKathy VincentXOMA Royalty CorporationKV Consulting & Management+1-646-438-9754+1-310-403-8951juliane.snowden@xoma.comkathy@kathyvincent.com

03 Dec 2024

·www.globenewswire.com

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets Seralutinib is being developed and co-commercialized by Gossamer Bio, Inc., and Chiesi Farmaceutici S.p.A; a Phase 3 study for pulmonary arterial hypertension is ongoing and is expected to read out in the fourth quarter of 20251 XOMA Royalty has the potential to net up to $25 million in milestone payments and earn a low to mid-single digit royalty Dec. 02, 2024 -- XOMA Royalty Corporation (NASDAQ: XOMA) announced today it now owns an economic interest in seralutinib, a Phase 3 asset being studied in pulmonary arterial hypertension (PAH), through its acquisition of Pulmokine Inc., a privately held company. In 2017, Pulmokine licensed seralutinib to Gossamer Bio, Inc., and in 2024, Gossamer Bio signed a global collaboration and license agreement with Chiesi Farmaceutici S.p.A. “We acquired Pulmokine to add seralutinib, a Phase 3 asset with strong mechanistic rationale in PAH, to our growing royalty and milestone portfolio while creating a favorable outcome for Pulmokine’s founders and stockholders. In addition, we believe seralutinib has the potential to address several cardio-respiratory conditions beyond PAH in the future,” stated Brad Sitko, Chief Investment Officer of XOMA Royalty. “This transaction marks the second whole-company acquisition we have completed in 2024. We continue to offer creative royalty capital solutions to access assets with the potential to deliver attractive returns to XOMA Royalty’s diverse portfolio.” XOMA Royalty acquired all outstanding shares of Pulmokine for a $20 million cash payment at closing. In addition, XOMA Royalty will pay success-based consideration contingent on future development and commercial events to Pulmokine stockholders. XOMA Royalty’s net royalties will range from the low to mid-single digits on commercial sales; additionally, the Company will retain up to $25 million of the milestone payments. XOMA Royalty was represented by Gibson, Dunn & Crutcher LLP. XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about XOMA Royalty and its portfolio, please visit www.xoma.com or follow the Company on LinkedIn. 1 https://ir.gossamerbio.com/news-releases/news-release-details/gossamer-bio-announces-third-quarter-2024-financial-results-and The content above comes from the network. if any infringement, please contact us to modify.

License out/inAcquisition

02 Dec 2024

·endpts.com

Senti Bio’s Phase 1 CAR-NK data; Allink raises $42M

Plus, news about Cytokinetics, Theratechnologies, KisoJi Biotechnology and XOMA Royalty: Senti Bio touts early Phase 1 CAR-NK data, stock soars: Two of three patients who received the low dose of Senti’s treatment achieved a complete response as of the Sept. 19 data cutoff. Senti expects to enroll 20 patients in the study. Its stock rose more than 150% in premarket trading on Monday, and the company also said it secured a $37.6 million PIPE. — Max Gelman China startup nabs $42M Series A: Allink Biotherapeutics, which was founded in 2023, is focused on bispecifics and antibody-drug conjugates. The money will help fund two pipeline programs called ALK201 and ALK202 through Phase 1 trials, as well as push forward other efforts in oncology and immunology. The round was led by Lanchi Ventures. — Max Gelman Cytokinetics’ heart drug gets FDA decision date: The biotech announced that the FDA has set a deadline of Sept. 26 to decide whether to approve aficamten for a heart condition called obstructive hypertrophic cardiomyopathy. The agency currently has no plans to hold an advisory committee. If approved, the treatment would compete with Bristol Myers Squibb’s Camzyos, which is currently the only cardiac myosin inhibitor approved in the US. — Lei Lei Wu Theratechnologies reveals financing: The Montreal biotech said it could get up to $75 million from TD Bank and Investissement Québec via credit facilities. Some of the loans will go toward paying off existing credit facilities and bankroll business development. The company had about $20 million in cash at the end of November. — Kyle LaHucik KisoJi gets $41M to advance TROP2 program: The company plans to use the money to get KJ-103, its lead compound, into Phase 1 testing for solid tumors. Funds include “the conversion of previously funded convertible debentures.” Investissement Québec and Lumira Ventures led the financing. — Max Gelman XOMA’s latest royalty deal: The royalty company bought Pulmokine for $20 million in cash. The move gives XOMA access to a milestone and royalty stream from Pulmokine’s interest in seralutinib, the pulmonary arterial hypertension drug it licensed to Gossamer Bio. The drug is now in Phase 3, with a readout slated for late 2025. — Kyle LaHucik

Phase 1Phase 3Drug ApprovalADC

100 Deals associated with XOMA Royalty Corp.

100 Translational Medicine associated with XOMA Royalty Corp.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 29 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Phase 1

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Resigratinib ( FGFR2 x FGFR3 )	Transitional Cell Carcinoma More	Phase 1
Xoma-3E ( BTX )	Botulism More	Phase 1
Insulin (Rezolute) ( INSR )	Diabetes Mellitus, Type 1 More	Phase 1
XOMA-3AB ( BTX )	Poisoning More	Phase 1
KIN-7324 ( CDK4 )	Neoplasms More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis